Radical cytoreductive prostatectomy in men with prostate cancer and oligometastatic disease
A Heidenreich, D Pfister - Current opinion in urology, 2020 - journals.lww.com
Patients with low-volume/low-risk metastatic prostate cancer (mPCA), good response to
neoadjuvant androgen deprivation therapy and a good Eastern Cooperative Onology Group …
neoadjuvant androgen deprivation therapy and a good Eastern Cooperative Onology Group …
Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases
Background Androgen deprivation therapy (ADT) represents the standard treatment for
hormone-naïve prostate cancer with systemic metastases (mPCA). The role of radical …
hormone-naïve prostate cancer with systemic metastases (mPCA). The role of radical …
Auranofin lethality to prostate cancer includes inhibition of proteasomal deubiquitinases and disrupted androgen receptor signaling
N Liu, Z Guo, X Xia, Y Liao, F Zhang, C Huang… - European journal of …, 2019 - Elsevier
Auranofin (Aur) inhibits thioredoxin reductases and is also an inhibitor of 19S proteasome
associated deubiquitinases, targeting USP14 and UCHL5. Androgen receptor is often over …
associated deubiquitinases, targeting USP14 and UCHL5. Androgen receptor is often over …
68Ga-PSMA ligand PET/CT-based radiotherapy for lymph node relapse of prostate cancer after primary therapy delays initiation of systemic therapy
C Henkenberens, CA Von Klot, TL Ross… - Anticancer …, 2017 - ar.iiarjournals.org
Aim: To evaluate 68Ga-PSMA ligand positron-emission tomography–computed tomography
(PET/CT)-based radiotherapy for lymph node metastases of prostate cancer after primary …
(PET/CT)-based radiotherapy for lymph node metastases of prostate cancer after primary …
[HTML][HTML] Baicalein suppresses the androgen receptor (AR)-mediated prostate cancer progression via inhibiting the AR NC dimerization and AR-coactivators interaction
D Xu, Q Chen, Y Liu, X Wen - Oncotarget, 2017 - ncbi.nlm.nih.gov
Background Androgen receptor (AR) plays a critical role in prostate cancer (PCa)
development and progression. Androgen deprivation therapy with antiandrogens to reduce …
development and progression. Androgen deprivation therapy with antiandrogens to reduce …
[HTML][HTML] A Retrospective Comparative Study of Sodium Fluoride Na18F-PET/CT and 68Ga-PSMA-11 PET/CT in the Bone Metastases of Prostate Cancer Using a …
K Kairemo, A Kangasmäki, SC Kappadath, T Joensuu… - Life, 2022 - mdpi.com
Bone is the most common metastatic site in prostate cancer (PCa). 68Ga-PSMA-11 (or
gozetotide) and sodium fluoride-18 (Na18F) are rather new radiopharmaceuticals for …
gozetotide) and sodium fluoride-18 (Na18F) are rather new radiopharmaceuticals for …
Final outcome of 223Ra-therapy and the role of 18F-fluoride-PET in response evaluation in metastatic castration-resistant prostate cancer–a single institution …
K Kairemo, DR Milton, E Etchebehere… - Current …, 2018 - ingentaconnect.com
Background: 223Ra was the first therapeutic alpha-emitting radionuclide registered for
clinical practice. This radionuclide is targeting actively bone-forming cells, and it is approved …
clinical practice. This radionuclide is targeting actively bone-forming cells, and it is approved …
[HTML][HTML] Is interim 18F-fluoride PET/CT a predictor of outcomes after radium-223 therapy?
E Etchebehere, AE Brito, K Kairemo, E Rohren… - Radiologia …, 2019 - SciELO Brasil
Objective: To determine whether an interim 18F-fluoride positron-emission
tomography/computed tomography (PET/CT) study performed after the third cycle of radium …
tomography/computed tomography (PET/CT) study performed after the third cycle of radium …
Lu-177-PSMA treatment for metastatic prostate cancer: Case examples of major responses
K Kairemo, T Joensuu - Clinical and Translational Imaging, 2018 - Springer
Prostate-specific membrane antigen (PSMA) is expressed in high-risk prostate cancer
(PCa). PSMA has potential as a basis for new diagnostics and theragnostics. 177 Lu-PSMA …
(PCa). PSMA has potential as a basis for new diagnostics and theragnostics. 177 Lu-PSMA …
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology?
P Blanchard, A Bossi, K Fizazi - Current Opinion in Urology, 2017 - journals.lww.com
Radiation therapy to the primary in metastatic prostate canc... : Current Opinion in Urology
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor …
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor …